CMV mismatch does not affect patient and graft survival in UK renal transplant recipients

Transplantation

Volumn 88, Issue 1, 2009, Pages 77-82

  Johnson, Rachel J ^a   Clatworthy, Menna R ^b,e   Birch, Rhiannon ^a   Hammad, Abdul ^c   Bradley, J Andrew ^d  

^a NHS BLOOD AND TRANSPLANT   (United Kingdom)

^b UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^c ROYAL LIVERPOOL UNIVERSITY HOSPITAL   (United Kingdom)

^d UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^e UK Transplant   (United Kingdom)

Author keywords

Allocation; Cytomegalovirus (CMV); Kidney transplant; Matching; Serostatus

Indexed keywords

VALGANCICLOVIR; ANTIVIRUS AGENT; IMMUNOSUPPRESSIVE AGENT; VIRUS ANTIBODY;

ADULT; ARTICLE; CHILD; CYTOMEGALOVIRUS INFECTION; GRAFT RECIPIENT; GRAFT SURVIVAL; HUMAN; INFECTION PREVENTION; KIDNEY ALLOGRAFT; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; UNITED KINGDOM; ADOLESCENT; ALLOTRANSPLANTATION; BLOOD; CYTOMEGALOVIRUS; DATA BASE; DISEASE TRANSMISSION; DONOR; IMMUNOLOGY; INFANT; KAPLAN MEIER METHOD; MIDDLE AGED; MORTALITY; NEWBORN; PRESCHOOL CHILD; PROPORTIONAL HAZARDS MODEL; RETROSPECTIVE STUDY; RISK ASSESSMENT; TIME; VIROLOGY;

ADOLESCENT; ADULT; ANTIBODIES, VIRAL; ANTIVIRAL AGENTS; CHILD; CHILD, PRESCHOOL; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; DATABASES AS TOPIC; GRAFT SURVIVAL; GREAT BRITAIN; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INFANT; INFANT, NEWBORN; KAPLAN-MEIERS ESTIMATE; KIDNEY TRANSPLANTATION; MIDDLE AGED; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; RISK ASSESSMENT; TIME FACTORS; TISSUE DONORS; TRANSPLANTATION, HOMOLOGOUS; YOUNG ADULT;

EID: 67651049214     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0b013e3181aa8d36     Document Type: Article

References (18)

1. Fishman JA, Rubin RH. Infection in organ-transplant recipients. N Engl J Med 1998; 338: 1741.
2. Rubin RH. Cytomegalovirus in solid organ transplantation. Transpl Infect Dis 2001; 3(suppl 2): 1.
3. Pouteil-Noble C, Ecochard R, Landrivon G, et al. Cytomegalovirus infection - An etiological factor for rejection? A prospective study in 242 renal transplant patients. Transplantation 1993; 55: 851.
4. Sagedal S, Nordal KP, Hartmann A, et al. The impact of cytomegalovirus infection and disease on rejection episodes in renal allograft recipients. Am J Transplant 2002; 2: 850.
5. Yilmaz S, Koskinen PK, Kallio E, et al. Cytomegalovirus infection-enhanced chronic kidney allograft rejection is linked with intercellular adhesion molecule-1 expression. Kidney Int 1996; 50: 526.
6. Humar A, Gillingham KJ, Payne WD, et al. Association between cytomegalovirus disease and chronic rejection in kidney transplant recipients. Transplantation 1999; 68: 1879.
7. Sagedal S, Hartmann A, Nordal KP, et al. Impact of early cytomegalo-virus infection and disease on long-term recipient and kidney graft survival. Kidney Int 2004; 66: 329.
8. Kliem V, Fricke L, Wollbrink T, et al. Improvement in long-term renal graft survival due to CMV prophylaxis with oral ganciclovir: Results of a randomized clinical trial. Am J Transplant 2008; 8: 975.
9. Lowance D, Neumayer HH, Legendre CM, et al. Valacyclovir for the prevention of cytomegalovirus disease after renal transplantation. International Valacyclovir Cytomegalovirus Prophylaxis Transplantation Study Group. N Engl J Med 1999; 340: 1462.
10. Valantine HA, Gao SZ, Menon SG, et al. Impact of prophylactic immediate posttransplant ganciclovir on development of transplant atherosclerosis: A post hoc analysis of a randomized, placebo-controlled study. Circulation 1999; 100: 61.
11. Opelz G, Dohler B, Ruhenstroth A. Cytomegalovirus prophylaxis and graft outcome in solid organ transplantation: A collaborative transplant study report. Am J Transplant 2004; 4: 928.
12. Guidelines for the prevention and management of cytomegalovirus disease after solid organ transplantation. 2004. Available at: http://www.bts.org.uk/ standards.htm. Accessed March 20, 2009.
13. Kamar N, Mengelle C, Esposito L, et al. Predictive factors for cytomegalo-virus reactivation in cytomegalovirus-seropositive kidney-transplant patients. J Med Virol 2008; 80: 1012.
14. Hughes D, Hafferty J, Fulton L, et al. Donor and recipient CMV serostatus and antigenemia after renal transplantation: An analysis of 486 patients. J Clin Virol 2008; 41: 92.
15. Costa C, Bergallo M, Cavallo R. Role of antiviral prophylaxis in renal transplant recipients at high risk of cytomegalovirus infection. J Clin Virol 2008; 42: 293.
16. Schnitzler MA, Lowell JA, Hardinger KL, et al. The association of cytomegalovirus sero-pairing with outcomes and costs following cadaveric renal transplantation prior to the introduction of oral ganciclovirCMV prophylaxis. Am J Transplant 2003; 3: 445.
17. Merion RM, Ashby VB, Wolfe RA, et al. Deceased-donor characteristics and the survival benefit of kidney transplantation. JAMA 2005; 294: 2726.
18. Pascual J, Zamora J, Pirsch JD. Asystematic review of kidney transplantation from expanded criteria donors. Am J Kidney Dis 2008; 52: 553.